Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
S-ketamine for perinatal depression after missed-abortion curettage
ChiCTR2200058731Phase 4Not yet recruiting
- Sponsor
- Nanjing Maternal and Child Health Hospital
- Start
- Mar 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of esketamine in Maternal depression (PND) and major depressive disorder (MDD) (3 arms), sponsored by Nanjing Maternal and Child Health Hospital. Primary endpoints: VAS score and EPDS score. Planned start Mar 2022; status: not yet recruiting.
02
Drugs
esketamine
03
Conditions
Maternal depression (PND)major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR2200058731.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200058731.